221 related articles for article (PubMed ID: 25956695)
1. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Kim TH; Jeong JW; Song JH; Lee KR; Ahn S; Ahn SH; Kim S; Koo TS
Arch Pharm Res; 2015 Nov; 38(11):2076-82. PubMed ID: 25956695
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
Lee KR; Jeong JW; Hyun HC; Jang E; Ahn S; Choi S; Joo SH; Kim S; Koo TS
Xenobiotica; 2018 Aug; 48(8):831-838. PubMed ID: 28803538
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Lee KR; Chae YJ; Koo TS
Xenobiotica; 2011 Dec; 41(12):1100-7. PubMed ID: 21838595
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetic Studies of Enzalutamide.
Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Ma H; Xu W; Ni J; Zhao N; Tang S; Li S; Cai T; Xiu J; Kang X; Gao S; Zhang L; Zhou T
Prostate; 2022 Feb; 82(2):276-285. PubMed ID: 34807458
[TBL] [Abstract][Full Text] [Related]
6. Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.
Ohtsu Y; Gibbons JA; Suzuki K; Fitzsimmons ME; Nozawa K; Arai H
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):611-626. PubMed ID: 27590197
[TBL] [Abstract][Full Text] [Related]
7. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characterization of the novel TAZ modulator TM-25659 using a multicompartment kinetic model in rats and a possibility of its drug-drug interactions in humans.
Lee KR; Choi SH; Song JS; Kwak EY; Chae YJ; Im SH; Lee BH; Seo H; Cho WK; Kim MS; Kim NJ; Ahn SH; Bae MA
Xenobiotica; 2013 Feb; 43(2):193-200. PubMed ID: 22856387
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.
Stüben J; Port R; Bertram B; Bollow U; Hull WE; Schaper M; Pohl J; Wiessler M
Cancer Chemother Pharmacol; 1996; 38(4):355-65. PubMed ID: 8674159
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of verproside after intravenous and oral administration in rats.
Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
[TBL] [Abstract][Full Text] [Related]
13. Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.
Shin BS; Hong SH; Bulitta JB; Hwang SW; Kim HJ; Lee JB; Yang SD; Kim JE; Yoon HS; Kim DJ; Yoo SD
J Toxicol Environ Health A; 2009; 72(21-22):1406-11. PubMed ID: 20077212
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
Hu ZY; Li XX; Du FF; Yang JL; Niu W; Xu F; Wang FQ; Li C; Sun Y
Acta Pharmacol Sin; 2013 Nov; 34(11):1437-48. PubMed ID: 24056706
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.
Koo TS; Kim SJ; Ha DJ; Baek M; Moon H
Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
17. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide.
Jiang J; Pang X; Li L; Dai X; Diao X; Chen X; Zhong D; Wang Y; Chen Y
Drug Des Devel Ther; 2016; 10():2181-91. PubMed ID: 27462143
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
Frick LW; St John L; Taylor LC; Painter GR; Furman PA; Liotta DC; Furfine ES; Nelson DJ
Antimicrob Agents Chemother; 1993 Nov; 37(11):2285-92. PubMed ID: 8285607
[TBL] [Abstract][Full Text] [Related]
20. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
